Hunter sendromu olarak da bilinen MPS II, idüronat 2-sülfataz (IDS) genindeki bir genetik mutasyona bağlı olup, glikozaminoglikanlar (GAG'ler) olan heparan ve dermatan sülfatın kusurlu parçalanmasına yol açarak hücre içi progresif GAG birikimine ve bunun sonucu olarak progresif, multisistemik hastalığa neden olur.1,2
Gözlemlenen hastalık semptomları
Hastalığın ilerlemesi
Genetik bilgiler
Önemli yönetim konuları
Referanslar: 1. Hopwood JJ et al. Molecular basis of mucopolysaccharidosis type II: mutations in the iduronate 2-sulphatase gene. Hum Mutat 1993;2(6):435–442. 2. Wraith JE et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167(3):267–277. 3. Scarpa M et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis 2011;6:72. 4. Baehner F et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005;28(6):1011–1017. 5. Guffon N et al. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study. Orphanet J Rare Dis 2015; 10:43. 6. Chkioua L et al. Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II. Diagn Pathol 2011;6:42.